Terry Mamounas, MD
Recent findings have suggested that 10 years versus 5 years of adjuvant hormone therapy reduces recurrence in women with primary breast cancer; however, the topic has been widely debated among researchers.
For example, results of the NSABP B-42 clinical trial, which were presented at the 2016 San Antonio Breast Cancer Symposium, found that extending letrozole therapy in women with early-stage, hormone receptor (HR)–positive breast cancer who completed 5 years of prior hormone therapy did not yield a statistically significant improvement in either disease-free or overall survival. However, data also showed that prolonged use of the aromatase inhibitor may be beneficial in some subgroups of women with a higher risk of recurrence.
... to read the full story